Axcynsis Therapeutics Pte Ltd. has described antibody-drug conjugates comprising an antibody or antigen-binding fragment targeting alkaline phosphatase placental type (ALPP) and/or alkaline phosphatase, germ cell type (ALPPL2) covalently linked to a cytotoxic agent through a linker reported to be useful for the treatment of cancer.
Allogenica SAS has been awarded a €2.5 million (US$2.7 million) grant under the French government’s France 2030 program to help advance its universal CAR T candidate, XL-001, for CD19-positive hematologic cancers.
Ampersand Biomedicines Inc. has secured $65 million in series B funding from investors including Ampersand’s founder, Flagship Pioneering, to support advancement of two lead programs and a new discovery partnership in obesity.
Researchers at Concept to Medicine Biotech Co. Ltd., Lepu Biopharma Co. Ltd. and Shanghai Miracogen Inc. have described antibody-drug conjugates consisting of trophoblast glycoprotein (TPBG, 5T4)-targeting antibodies covalently linked to cytotoxic drugs through linkers reported to be useful for the treatment of cancer.
Sotio Biotech AS is exercising an option under a license and option agreement to obtain a license to Synaffix BV’s technology to develop two bispecific antibody-drug conjugate (ADC) programs for solid tumors.
Sutro Biopharma Inc. has announced plans to prioritize its three wholly owned preclinical programs in its next-generation antibody-drug conjugate (ADC) pipeline, while deprioritizing additional investment into development of luveltamab tazevibulin across all indications.
Inatherys SAS recently presented preclinical data for INA-03, an anti-transferrin receptor (TfR1/CD71) antibody-drug conjugate (ADC), being developed for the treatment of triple-negative breast cancer (TNBC). INA-03 was constructed by conjugating an antimitotic payload (MMAE) to a humanized IgG4 anti-human CD71 antibody using a novel valine-citrulline linker.
Finnish cancer immunotherapy specialist Valo Therapeutics Oy has raised €19 million (US$20.7 million) in a round that attracted Italian and Australian investors, and funding the company to the completion of the ongoing phase Ib trial of its lead program in the treatment of solid tumors.
Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), is one of the most prevalent digestive malignancies, with a 5-year survival rate of only 20%. Although some cancer immunotherapies based on immune checkpoint inhibitors (ICIs) have shown promise for ESCC, only a minority of patients actually benefit from ICI therapy.
RSS
